Hyundai Motor’s STARIA MPV Debuts, Pioneering Future of Mobility with Safety and Versatility

– STARIA embodies Hyundai Motor’s new ‘inside-out’ design methodology, establishing a model for Purpose Built Vehicle in future mobility era

– Maximized space utilization, flexible seating with long sliding capability, along with highest level of safety make STARIA suitable for business and family

– Hyundai plans to add STARIA Special Vehicle lineups and eco-friendly variants in the upcoming years

SEOUL, South Korea, April 13, 2021 /PRNewswire/ — Hyundai Motor Company today officially launched its new STARIA multi-purpose vehicle (MPV) lineup via a digital world premiere, establishing a model for its future Purpose Built Vehicles (PBVs).

Experience the interactive Multimedia News Release here:

STARIA’s debut furthers Hyundai Motor’s transformation as a Smart Mobility Solution Provider and embodies the company’s ‘inside-out’ design methodology that emphasizes interior spaciousness and usability. STARIA is Hyundai’s response to shifting consumer needs by offering them purposeful, innovative features and redefining in-car travel experiences in line with the company’s vision of ‘Progress for Humanity.’

STARIA is available in 2- to 11-seat configurations and in two variants: STARIA and STARIA Premium, the latter elevating mobility to the next level with upgraded features and variant-exclusive finishes for a more luxurious look and feel.

“We are thrilled to introduce STARIA, which represents our latest effort to spearhead the evolution of mobility, and to address emerging lifestyle needs as we adapt to new ways of living, said Thomas Schemera, Executive Vice President and Global Chief Marketing Officer. “STARIA is a step forward in connecting us more closely with our environments so that we can get more out of our everyday lives and do more for ourselves in transit.”

STARIA will go on sale in select markets starting from the second half of 2021.

For a full article and additional images, please visit:

Related Links :

Gemini Earn is now available for Singapore Customers

SINGAPORE, April 13, 2021 /PRNewswire/ — Gemini, a crypto exchange and custodian, today announced the launch of its new interest-earning program Gemini Earn in Singapore. With Gemini Earn, customers can transfer existing crypto holdings, or easily purchase crypto to transfer into Gemini Earn and earn up to 7.4% interest on 28 cryptocurrencies available on Gemini. Gemini Earn customers can also redeem their crypto at any time.

“We’re excited to bring Gemini Earn to Singapore. Gemini Earn was specially designed to allow users to invest in the long term while still generating real returns on their crypto holdings. As Gemini grows in Asia, my team and I are glad to be introducing some of the best Gemini products and programmes to our customers in Singapore,” says Jeremy Ng, Head of Asia Pacific at Gemini.

The launch of Gemini Earn in Singapore follows recent news that Gemini Earn has been launched in all 50 states in the US and that Gemini customers are now collectively earning interest on more than $1 billion in loans originated through Gemini Earn. Visit to learn more.

About Gemini in Singapore

Gemini Digital Payments Pte Ltd, an affiliate of Gemini Trust Company LLC, is a Digital Payment Token exchange and custodian business in Singapore, allowing customers to trade and store Digital Payment Tokens and to exchange such tokens with fiat currencies, including Singapore Dollars. Gemini Digital Payments operates under the supervision of the Monetary Authority of Singapore and has applied for a Major Payment Institution License pursuant to the regulations set forth in the Payment Services Act 2019.

Media contact

Hanna Tantoco
Marketing Communications – APAC

Related Links :

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, April 13, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced with Eli Lilly and Company (“Lilly”, NYSE: LLY) that the results of the Phase 3 ORIENT-3 study were released today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.

ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population (280 patients, excluding patients on the docetaxel arm who received immunotherapy prior to disease progression), TYVYT® (sintilimab injection) demonstrated a statistically significant improvement in overall survival (OS) compared to docetaxel, meeting the pre-specified primary endpoint. The median OS was 11.79 months for patients on the TYVYT® (sintilimab injection) arm and 8.25 months for those on the docetaxel arm (HR=0.74, 95% CI: 0.56-0.96, P=0.02489). The median progression-free survival (PFS) as assessed by investigators was 4.30 months versus 2.79 months (HR=0.52, 95% CI: 0.39-0.68, P<0.00001), and the confirmed objective response rate (ORR) was 25.5 percent versus 2.2 percent (P<0.00001), respectively. Safety was consistent with previous studies of TYVYT® (sintilimab injection), and no new safety signals were identified.

Professor Yuankai Shi, principal investigator of ORIENT-3, Associate Dean of Cancer Hospital, Chinese Academy of Medical Sciences and Chairman of Cancer Foundation of China, stated: “Lung cancer is the leading cause of cancer death globally, of which non-small cell lung cancer accounts for 80 to 85 percent. In the past few decades, drug development of non-small cell lung cancer has mainly focused on nonsquamous non-small cell lung cancer, while drug development of squamous non-small cell lung cancer has been slower due to its unique epidemiological, histopathological and molecular characteristics. In China, specifically, the approved options for second-line immunotherapy to treat squamous non-small cell lung cancer are even more limited. The ORIENT-3 study showed that the anti-PD-1 monoclonal antibody sintilimab significantly improved overall survival for the second-line treatment of squamous non-small cell lung cancer patients, which is of great clinical value. We hope that the positive results of ORIENT-3 can help more squamous non-small cell lung cancer patients.”

“TYVYT® (sintilimab injection) was the first anti-PD-1 inhibitor included in the New Catalogue of the National Reimbursement Drug List in 2019,” said Dr. Hui Zhou, Vice President of Medical Science and Strategy Oncology of Innovent. “In August 2020, the NMPA accepted a new indication application for TYVYT® (sintilimab injection) in combination with chemotherapy for first-line treatment of squamous NSCLC. In the ORIENT-3 study, sintilimab as second-line monotherapy demonstrated a significantly improved survival benefit for patients with advanced squamous non-small cell lung cancer, and we look forward to the potential approval of this indication, to help more patients with this type of lung cancer.”

“We are excited about these results, showing TYVYT® (sintilimab injection) significantly improved overall survival in this patient population. This study underscores the joint commitment from Lilly and Innovent to provide innovative treatment options to patients with lung cancer,” said Dr. Wang Li, Senior Vice President of Lilly China and Head of Lilly China Drug Development and Medical Affairs. “We would like to thank the patients, the investigators, the clinical trial centers and our colleagues from Innovent that are involved in the study. We look forward to working together to potentially bring this new treatment option to people in China with squamous non-small cell lung cancer.”

About Squamous NSCLC

Lung cancer is a malignancy with the highest morbidity and mortality in China. NSCLC accounts for about 80 to 85 percent of lung cancer. Approximately 70 percent of people with NSCLC have locally advanced or metastatic NSCLC at initial diagnosis, rendering many of those patients with no chance of radical resection. Meanwhile, even after radical surgery, patients still have a high chance of recurrence and eventually die from disease progression. About 30 percent of people in China with non-small cell lung cancer have tumors of the squamous subtype and there are limited approved second-line therapies for these patients. Therefore, there remains a huge unmet medical need in China.

About the ORIENT-3 Trial

ORIENT-3 is a randomized, open-label, multi-center, Phase 3 clinical trial to evaluate the efficacy and safety of TYVYT® (sintilimab injection) as second-line therapy for advanced or metastatic sqNSCLC (, NCT 03150875). The primary endpoint is overall survival (OS). The secondary endpoints include progression-free survival (PFS) as assessed by investigators based on RECIST v1.1, objective response rate (ORR) and safety profile.

A total of 290 patients were enrolled in ORIENT-3 and randomized in a 1:1 ratio to receive either TYVYT® (sintilimab injection) 200mg or docetaxel every three weeks. The patients received treatment until radiographic disease progression, unacceptable toxicity or any other conditions that require treatment discontinuation.

About TYVYT® (Sintilimab Injection)

TYVYT® (sintilimab injection), an innovative drug with global quality standards jointly developed in China by Innovent and Lilly, has been granted marketing approval by the NMPA (National Medical Products Administration) for the treatment of relapsed or refractory classic Hodgkin’s lymphoma after two lines or later of systemic chemotherapy, and is included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. In February 2021, TYVYT® (sintilimab injection) was approved by the China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for the treatment of nonsquamous non-small cell lung cancer. TYVYT® (sintilimab injection) was included in the National Reimbursement Drug List (NRDL) in November 2019 as the first PD-1 inhibitor and the only PD-1 included in the list in that year.

Currently TYVYT® (sintilimab injection) has three supplemental New Drug Applications (“sNDA”) under review by the NMPA. In August 2020, the NMPA accepted the sNDA for TYVYT® (sintilimab injection) in combination with gemcitabine and platinum chemotherapy as first-line therapy in squamous NSCLC. In January 2021, the NMPA accepted the sNDA for TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab injection) as first-line therapy in Hepatocellular Carcinoma (HCC) and the sNDA for TYVYT® (sintilimab injection) as second-line therapy in squamous NSCLC. Besides, in May 2020, TYVYT® (sintilimab injection) monotherapy met the primary endpoint of overall survival in the Phase 2 ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

TYVYT® (sintilimab injection), is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies with TYVYT® (sintilimab injection) to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Meanwhile, Innovent is conducting clinical research studies on TYVYT® (sintilimab injection) worldwide.

About Innovent

Inspired by the spirit of “Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection) and HALPRYZA® (rituximab biosimilar injection) – officially approved for marketing in China, five assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical trials. TYVYT® (sintilimab injection) was the first PD-1 inhibitor included in the NRDL.
Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China’s biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients’ lives.  For more information, please visit:

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at

About Innovent Biologics’ strategic collaboration with Eli Lilly and Company

Innovent entered into a strategic collaboration with Lilly focused on biological medicine in March 2015 – a groundbreaking partnership between a Chinese pharmaceutical company and a multinational pharmaceutical company. Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT® (sintilimab injection), in China. In October 2015, the two companies announced the extension of their existing collaboration to include co-development of three additional oncology antibodies targeting oncology indications. In August 2019, Innovent further entered a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China. Its collaboration with Lilly indicates that Innovent has established a comprehensive level of cooperation between China’s innovative pharmaceuticals sector and the international pharmaceuticals sector in fields such as R&D, CMC, clinical development and commercialization. In August 2020,Lilly and Innovent announced a global expansion of their strategic alliance for TYVYT® (sintilimab injection), whereby Lilly obtained an exclusive license for TYVYT® (sintilimab injection) for geographies outside of China and plans to pursue registration of TYVYT® (sintilimab injection) in the U.S. and other markets.

TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection) is not an approved product in the United States.
SULINNO® (adalimumab biosimilar injection) is not an approved product in the United States.
HALPRYZA® (rituximab biosimilar injection) is not an approved product in the United States.

TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)

ALIMTA® and GEMZAR® are trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.


1. This indication is still under clinical trial, which hasn’t been approved in China.
2. Innovent does not recommend any off-label usage.
3. For medical and healthcare professionals only.

Related Links :

Pengana Capital Group to host 9-part investment webinar series across it’s diverse range of specialities

SYDNEY, April 13, 2021 /PRNewswire/ — Starting in April and running for 9 weeks through to June, Pengana Capital Group will be hosting 9 webinars representing over $55billion of investment management insights across various portfolios, presented by leading fund managers from around the world. Together, these managers cover Australian and International equities spanning impact investing, healthcare, Israeli tech, property, small caps and private equity, and will host webinar presentations and open discussions on their markets and notable holdings. 

“It has certainly been an exceptionally interesting period in history for investors: a global pandemic followed by vaccine rollout programs, record-low interest rates, Brexit, American elections, the rise of work from home fuelling rapid global adoption of technology, the list goes on. Pengana is excited to present this series of investment updates, market commentary, and reporting season insights from our diverse range of independent fund managers,” Pengana Capital Group’s CEO Russel Pillemer said. 

The webinar series promises to be a great forum to hear directly from experts, providing unique insights and assessments of the investment landscape, as well as opportunities and stock-specific overviews that feed into each manager’s portfolio construction in the current climate.

Each webinar will be FPA-accredited to provide CPD points for Australian financial advisers, and there will be a question and answer component in each session for attendees to query our experts directly.

Previous webinar series hosted by Pengana’s range of fund managers have been extremely well received by financial advisers and direct investors alike, with significant continued growth in registrants for each webinar series.

Registration for the webinars is now open, and available HERE

Webinars include:

Session 1: Emerging Australian companies with Ed Prendergast | Tuesday, 13 April 2021 9:00 AM (AEST)

Session 2: Australian equities with Rhett Kessler | Tuesday, 20 April 2021 9:00 AM (AEST)

Session 3: Impact investing with Ted Franks | Tuesday, 27 April 2021 4:00 PM (AEST)

Session 4: Australian property with Amy Pham | Tuesday, 4 May 2021 9:00 AM (AEST)

Session 5: Private Equity with Frederick E. Pollock | Tuesday, 11 May 2021 9:00 AM (AEST)

Session 6: International equities with James McDonald | Tuesday, 18 May 2021 9:00 AM (AEST)

Session 7: Healthcare stocks with James McDonald | Tuesday, 25 May 2021 9:00 AM (AEST)

Session 8: Global small caps with Jon Moog | Tuesday, 1 June 2021 9:00 AM (AEST)

Session 9: Israeli tech innovation with Gabi Dishi | Tuesday, 8 June 2021 4:00 PM (AEST)

Contact:, +61 2 8524 9900

Related Links :


Cobre del Mayo, S.A. de C.V. Announces an Exchange Offer for its Senior Secured PIK Toggle Notes Due 2021

MEXICO CITY, April 13, 2021 /PRNewswire/ — Cobre del Mayo, S.A. de C.V. announced today that it has commenced an exchange offer for any and all of its outstanding Senior Secured PIK Toggle Notes due 2021. Please click to the link below to see the press release that summarizes the terms and conditions of the exchange offer and indicates how noteholders eligible to participate in the offer can receive documentation relating to the offer. Securities offered in the exchange offer will not be registered under the U.S. Securities Act and are offered pursuant to applicable exemptions from the registration requirements of the Act.

The press release is also available through the website


Ismitz Matthew De Alwis, Chief Executive Officer of Kenanga Investors Berhad

Kenanga Investors Completes Distribution of Over RM 531m

KUALA LUMPUR, Malaysia, April 12, 2021 /PRNewswire/ — Kenanga Investors Berhad (“Kenanga Investors”) has declared a final income distribution of RM256.0 million for 21 retail funds till March 2021 adding to the earlier RM275.7 million that has been distributed and also income repatriation during the course of 2020, making it a record-breaking total distribution amount of RM531.7 million for its clients for financial year 2020.

Ismitz Matthew De Alwis, Chief Executive Officer of Kenanga Investors Berhad
Ismitz Matthew De Alwis, Chief Executive Officer of Kenanga Investors Berhad

Ismitz Matthew De Alwis, Executive Director and Chief Executive Officer of Kenanga Investors said, “We are proud to declare an income distribution for a wide range of funds under our management. Income distribution yields ranged from 8% to 12% for equity and balanced funds while fixed income funds generated average yields of 6%.”

The income distribution was derived from the funds’ realised gains, dividends and other income across equity, fixed income and mixed asset classes, which included the firm’s flagship funds Kenanga Growth Fund and Kenanga Syariah Growth Fund.

“The outperformance from our funds echoes our superior bottom-up stock selection in small-and-mid cap counters, many of which have exhibited strong earnings growth in the past few years, including 2020. Kenanga Investors’ long-standing firmwide commitment towards a ‘Consistent Top Performance‘ philosophy is reflected even when markets are volatile, as we strive to protect and hedge risk while taking advantage of positive conditions,” said De Alwis.

Despite this stellar performance, the past year was not without its challenges as many segments of the economy were affected due to the lockdowns. De Alwis maintains that the key factor was to avoid panic selling while adhering to the firm’s investment strategy and stringent risk management framework which allowed it to identify key companies which were best positioned during the period.

“For 2021, we have structured our approach to centre on recovery and growth themes with vaccination programs progressing and the perpetual interest in tech and electronics. Moving forward, we recognise the growing demand within the IT infrastructure industry stemming from the work-from-home movement. We are excited by these rising trends and remain committed to embracing them by developing products that are relevant and sustainable that would enable our clients to build a more diversified portfolio,” De Alwis added.

Since 2019, Kenanga Investors has completed two major acquisition exercises to expand its foothold within the asset and wealth management space, first with award-wining fixed income expert Libra Invest Berhad in 2019 and most recently with i-VCAP Management Sdn Bhd, the first Shariah exchange-traded fund (“ETF”) issuer in Malaysia, early this year. Known for its alternative line of products, it has launched several milestone products in the industry including the first artificial intelligence driven fund, Kenanga Global Multi Asset Fund, the start-up focused Kenanga Global Unicorn Series and the first KLCI-benchmarked leveraged and inverse ETFs.

As at 28 February 2021, the firm manages 38 unit trust funds, 2 private retirement schemes (consisting of 6 core funds and 1 non-core fund), 6 exchange-traded funds (ETFs), 29 wholesale funds and other funds from government agencies, pension funds, insurance, corporate and individual clients with total assets under administration amounting to RM14.7 billion.

For more information about Kenanga Investors Berhad, please visit

Related Links :

Thailand Introduces Largest Inter-Agency Collaboation to Raise MICE SAFETY STANDARD in 10 MICE Cities

Thailand Introduces Largest Inter-Agency Collaboation to Raise MICE SAFETY STANDARD in 10 MICE Cities

BANGKOK, April 12, 2021 /PRNewswire/ — Thailand Convention and Exhibition Bureau (TCEB) and 22 organisations signed Memorandum of Understanding (MOU) to jointly upgrade disease control and hygiene measures for MICE industry in 10 MICE cities nationwide.

Thailand Introduces Largest Inter-Agency Collaboation to Raise MICE SAFETY STANDARD in 10 MICE Cities
Thailand Introduces Largest Inter-Agency Collaboation to Raise MICE SAFETY STANDARD in 10 MICE Cities

Spearheaded by TCEB and Department of Health under the Ministry of Public Health, the effort aims to boost confidence for MICE throughout the country with heightened disease control measures.

Witnessing the signing of MoU was Deputy Prime Minister and Minister of Public Health, Mr. Anutin Charnvirakul, who in his speech reaffirmed the government’s priority for public health and nationwide vaccination programme to revive tourism and the economy. The MOU is the largest inter-agency initiative aimed at revitalising MICE to date.

The 10 MICE cities signing MOU comprise Bangkok, Chiang Mai, Pattaya, Phuket, Khon Kaen, Nakhon Ratchasima, Song Khla, Udon Thani, Phitsanulok and Surat Thani. To kick off the campaign, road show was organised in Phuket on April 5, 2021. It will be rolled out in Khon Kaen, Chiang Mai, Udon Thani, Pattaya and Bangkok. The targets include MICE-related organisations such as venues, event organisers, hotels, transport providers, restaurants, retail establishments, and department stores.

The overall goal is to enable the practice of upgraded health measures in all MICE activities. TCEB is ready to assist participating organisations in applying the upgraded safety standard so that they can operate with increased confidence in line with the progress of Thailand’s vaccination programme.

TCEB President, Mr Chiruit Isarangkun Na Ayuthaya, said: “This new initiative gives MICE-related organisations throughout Thailand a single point of contact for implementing the most comprehensive health and safety protocols for every MICE activity. It integrates a number of programmes such as TCEB’s MICE Cities Development Plan, MICE New Normal, Thailand MICE Venue Standard (TMVS), Thai Stop COVID Plus campaign of the Department of Health, and Amazing Thailand Health and Safety Administration (SHA) by the Tourism Authority of Thailand (TAT). This signals that Thailand is mobilizing the strongest public-private partnership to revive MICE in Thailand and contribute to the recovery of the economy.”

Other than the local governments of the 10 MICE cities, the signing partners of the MOU are the Department of Disease Control, Department of Health, Department of Tourism, Department of Land Transport, Department of Airports, Tourism Authority of Thailand, Federation of Thai Industries, Tourism Council of Thailand, Board of Trade of Thailand, Thai Hotels Association, Airports of Thailand PCL, Airlines Association of Thailand.

Related Picture :

About TCEB


Established in 2004, Thailand Convention & Exhibition Bureau (Public Organization) or TCEB – the government agency under the supervision of the Prime Minister – has been assigned a role to promote, support and develop business events industry – corporate meetings, incentive trips, conventions, exhibitions, mega events and world festivals. Serving as a strategic partner, TCEB helps deliver creative ideas and solutions to bring success and fulfill the requirements of business events. The overarching goal is to drive Thailand to become a global MICE and mega events destination that can drive the country’s strategic industries and national economy.

Related Links :

The patented CoolJet is a double-layer apparel fitted with a temperature modulating device. It allows cool air to flow through the entire jacket between the layers, while heat is dissipated into the surroundings.

Sino Group Innovations Garner Gold Medals at 2021 Geneva International Exhibition of Inventions

HONG KONG, April 10, 2021 /PRNewswire/ — Two home-grown Sino Group (the ‘Group’) inventions, the CoolJet and Mobile Indoor Air Quality (IAQ) Robot, were presented Gold Medals at the 2021 Special Edition of the Geneva International Exhibition of Inventions. About 600 inventions were presented by hundreds of exhibitors from 20 countries and regions at the exhibition which was held virtually this March.

The patented CoolJet is a double-layer apparel fitted with a temperature modulating device. It allows cool air to flow through the entire jacket between the layers, while heat is dissipated into the surroundings.
The patented CoolJet is a double-layer apparel fitted with a temperature modulating device. It allows cool air to flow through the entire jacket between the layers, while heat is dissipated into the surroundings.

The CoolJet received the champion award while the Mobile IAQ Robot was selected as one of the finalists at the 2019 inaugural Sinovation programme, the group-wide Sino Group innovation programme. It aims to encourage the origination of creative technology solutions to drive efficiency in daily operations and improve quality of life. 

The CoolJet is a patented technology that was designed as a ‘wearable air conditioner’ for use in working environments where ventilation and high temperature are concerns. This innovative idea for double-layer apparel, fitted with a temperature modulating device comprising a thermoelectric cooler, air distribution system and cooling system, allows cool air to flow through the entire jacket between the layers while heat is dissipated into the surroundings.

The other Gold Medal recipient, the self-navigating Mobile IAQ Robot equipped with a proprietary dashboard and management system, serves as an indoor air quality detector and display for continuous inspection of up to nine IAQ parameters including fine suspended particles PM1, PM2.5 and PM10. It also allows real-time access to IAQ data on the robot’s screen and online dashboard to enable immediate implementation of remedial measures and improvements.

‘Sino Group sees innovation as the path to our future. We are dedicated to nurturing a culture of innovation within the Group, and took a step further to support the development of CoolJet concept for practical use. We care about the well-being of our frontline colleagues, and hope this CoolJet will contribute to an even safer and more comfortable working environment for all, particularly in the hot and humid climate of Hong Kong and Singapore,’ Mr Daryl Ng, Deputy Chairman of Sino Group remarks, ‘There are over 130 entries from Hong Kong this year, and we are honoured by the prestigious, international recognition and are pleased to see innovations from Hong Kong and the inventions of our colleagues featured in the international arena. These accolades are testament to the Group’s continuous commitment to supporting Hong Kong’s innovation ecosystem and growth into an international technology hub.’

First launched in June 2019, Sinovation aims to nurture an innovative culture within the Group. Over 130 innovations resulted from the inaugural programme. Funding was provided to shortlisted projects to help convert their concepts into functional prototypes. The second Sinovation programme launched just recently in March this year. The submissions are now under review and shortlisted ideas will be selected for proceeding to the ‘learn & grow’ stage.

About Sino Group

Sino Group is one of the leading property developers in Hong Kong. It comprises three listed companies – Sino Land Company Limited (HKSE: 0083), Tsim Sha Tsui Properties Limited (HKSE: 0247) and Sino Hotels (Holdings) Limited (HKSE: 1221) as well as private companies held by the Ng Family.

The Group’s core business is developing residential, office, industrial and retail properties for sale and investment. In addition to an extensive portfolio in Hong Kong, the Group has footprints in mainland China, Singapore and Australia. The Group has developed more than 250 projects, spanning a total plot ratio area of over 84.6 million sq ft. Our core business is complemented by the gamut of property services encompassing management, security and environmental services to ensure a seamless Sino Experience. We are also a key player in hotel and club management.

The Group employs more than 10,000 committed staff members, who share the vision of creating better lifescapes. Lifescape is our vision – to build a better life together, where the community thrives in harmony by embracing green living and wellness, by engaging with all and pursuing meaningful designs, and by seeking innovation while respecting heritage and culture. Committed and together, we create a better community where people live, work and play. In the year 2021, the Group celebrates its 50th anniversary, commemorating our five decades of community-building and dedication to Creating Better Lifescapes.

The Group focuses its sustainability efforts on three areas, namely Green Living, Innovative Design, and Community Spirit. Sino Land Company Limited (083) has been a constituent member of the Hang Seng Corporate Sustainability Index Series since September 2012 for its continual efforts in promoting sustainability.

Kuke Music Holding Limited to Report Fourth Quarter and Full Year 2020 Financial Results on April 15, 2021

BEIJING, April 10, 2021 /PRNewswire/ — Kuke Music Holding Limited (“Kuke” or the “Company”) (NYSE: KUKE), a leading provider of classical music licensing, subscription and education services in China, today announced that it plans to release its unaudited financial results for the fourth quarter and full year of 2020 after the U.S. market closes on Thursday, April 15, 2021. The earnings release will be available on the Company’s investor relations website at

Kuke’s management will hold a conference call on Thursday, April 15, 2021 at 8:00 P.M. Eastern Time (Friday, April 16, 2021 at 8:00 A.M. Beijing/Hong Kong Time) to discuss the financial results. Listeners may access the call by dialing the following numbers:



United States Toll Free:  


Mainland China Toll Free: 


Hong Kong Toll Free:


Conference ID: 

Kuke Music Holding Limited

A replay of the conference call will remain accessible for one week after the live event by dialing the following numbers:



United States Toll Free: 


Access Code:


A live and archived webcast of the conference call will also be available at the Company’s investor relations website at

About Kuke Music Holding Limited

Kuke Music Holding Limited (“Kuke”) is the leading provider of classical music licensing, subscription, and education services in China. As of December 31, 2019, Kuke had the largest library of classical music content in China and, in 2019, Kuke was the largest classical music licensing service provider and the second largest online classical music subscription service provider in China, according to Frost & Sullivan. Kuke leverages its rich and diverse content offerings and deep expertise in music education to offer innovative and efficient smart music education solutions, which primarily consist of its proprietary Kuke smart pianos, Kuke smart teaching systems and Kukey courses. Kuke is also the organizer of several live classical musical events in China, including the Beijing Music Festival, which is one of the most renowned musical events in the world. Through these three highly synergistic business lines, Kuke has formed a thriving content-centric ecosystem, positioning it well to continuously provide its customers with differentiated value propositions.

Investor Relations Contact

Kuke Music Holding Limited
Phone: +1 (212) 321-0602

Related Links :

Mission Peak Capital Acquires Stake in Mount Street US

Investment firm intends to accelerate US primary and special servicing business

KANSAS CITY, Mo., April 10, 2021 /PRNewswire/ — Mission Peak Capital (MPC), a US-based real estate investment company founded on the concept of smart growth through real estate cycles, announces today a significant financial investment in the US operations of global servicing company, Mount Street Group. Mount Street is the largest third-party loan servicer in Europe, where it oversees over $95B of credit services, and seeks to grow its US presence while providing more customized, bespoke servicing by leveraging Mission Peak Capital’s deep understanding of commercial real estate cycles. Together, the companies are positioned to lead the industry in high-touch servicing combined with the most holistic perspective of a commercial real estate investment’s lifecycle. 

“Our investment in Mount Street is a direct result of our recognition that commercial real estate is evolving and continues to be deeply impacted by changing global trends,” stated Wit Solberg, Principal and Founder of Mission Peak Capital. “Investors are seeking yield and purchasing increasingly complicated investment vehicles further up the credit curve which will require an experienced servicing partner. This partnership will not only benefit investors with more customized solutions–lenders and borrowers will all gain advantage from a servicing provider that truly understands real estate from an asset level to ensure success.”

“This joint venture will enable our global clients to have further reach in US capital markets,” noted Ravi Joseph, Founder, Managing Partner and CEO of Mount Street. “We see this is an advantageous partnership that will position our international brand as a truly differentiated, bespoke solution with an all-encompassing offering unmatched by other competitors. Too often, firms are hired to service loans without direct knowledge of the actual product: the property itself. The MPC/Mount Street joint venture has ‘on-the-ground,’ first-hand expertise with global real estate assets and operations to deliver the utmost value to clients.”

MPC is intrinsically involved in every aspect of CRE including loan origination, bond servicing, B-piece bond investing, equity ownership and property management. MPC’s portfolio of investments and expertise creates a differentiated CRE servicing platform, one known for matching opportunities that align with the current real estate market cycle. Mount Street launched US operations in 2017 and currently oversees $12B in assets under management (AUM). 

This partnership will expand beyond its Atlanta and New York offices and add up to 20 new, seasoned servicing and asset management professionals in Atlanta and its new office in Kansas City. 

For more information about Mission Peak Capital’s investment in Mount Street, visit its website,

About Mission Peak Capital 
Mission Peak Capital (MPC) is a real estate investment company founded on the concept of smart growth through real estate cycles. Founded in 2008, the company is forward-thinking and ever-evolving, having grown from its roots in CMBS bond advisory to a fully integrated commercial real estate (CRE) platform encompassing debt, equity, servicing and property management. At MPC, a customized approach to commercial real estate enhances a dynamic portfolio of real estate investments. 

About Mount Street Group
Mount Street is an independent business that has grown rapidly since being founded in 2013 and now has a global footprint that offers unparalleled service to its clients. Globally, Mount Street oversees $95B of credit products with a team of more than 150 professionals in 10 offices. Having launched US operations in 2017, Mount Street US currently oversees $12B in assets under management (AUM). As the largest third-party CRE servicer in Europe and a global leader across the credit asset-backed and structured finance markets in Europe, Australia and the United States, Mount Street was awarded CRE Servicer of the Year in 2016, 2017, 2018 and 2019 by the readers of Real Estate Capital and is the European market leader in CMBS servicing. Mount Street provides services across the front, middle and back-office to our clients throughout the loan lifecycle, with market leading expertise, a trusted team of professionals and a proprietary technology system driving service excellence.